CN111727981A - Spray containing microcapsule sustained-release composition and preparation method and application thereof - Google Patents
Spray containing microcapsule sustained-release composition and preparation method and application thereof Download PDFInfo
- Publication number
- CN111727981A CN111727981A CN202010455360.6A CN202010455360A CN111727981A CN 111727981 A CN111727981 A CN 111727981A CN 202010455360 A CN202010455360 A CN 202010455360A CN 111727981 A CN111727981 A CN 111727981A
- Authority
- CN
- China
- Prior art keywords
- parts
- oil
- spray
- microcapsule
- release composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/26—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests in coated particulate form
- A01N25/28—Microcapsules or nanocapsules
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
- A01N59/16—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
- A01N65/08—Magnoliopsida [dicotyledons]
- A01N65/28—Myrtaceae [Myrtle family], e.g. teatree or clove
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/04—Making microcapsules or microballoons by physical processes, e.g. drying, spraying
- B01J13/043—Drying and spraying
Abstract
The invention discloses a spray containing a microcapsule slow-release composition, and a preparation method and application thereof. The spray comprises a microcapsule slow-release composition; the microcapsule sustained-release composition comprises the following raw materials in parts by weight: in the composition, octenyl succinate starch ester is taken as a wall material, and the core material comprises 2-10 parts of atractylodes oil, 2-20 parts of patchouli oil, 2-30 parts of angelica dahurica oil, 3-15 parts of eupatorium oil, 3-7 parts of cinnamon oil, 2-8 parts of camphor oil, 5-15 parts of clove oil, 2-25 parts of eucalyptus oil and 2-8 parts of mint oil. After spraying, the function of killing pathogenic microorganisms in vitro of the traditional Chinese medicine essential oil can be actively exerted, and the release effect of the antibacterial active ingredients is durable. The microcapsule slow-release composition has no toxic or side effect and adverse reaction, has low spray cost and simple and feasible process, is suitable for industrial production and is suitable for clinical popularization and application.
Description
Technical Field
The invention belongs to the field of antibiosis and antivirus, and particularly relates to a spray containing a microcapsule slow-release composition, and preparation and application thereof.
Background
And (3) sterilization and antivirus of the essential oil: at the end of the nineteenth century, scientists have studied the bactericidal effect of essential oils. In the thirties of the twentieth century, the term aromatherapy (Aro-matherapie) was proposed by the French person Rene-M aurice Gattefose. Since then, aromatherapy has been abandoned by people due to the advent of the antibiotic age. By the sixties of the twentieth century, the british aromatherapy expert dr. She has established several schools in succession in the uk. The specialized teaching of aromatherapy has led thousands of physicians to gain an understanding of various anti-infective techniques that are not known in medical institutions. To meet the needs of the colleagues, the pharmacists and some biological laboratories engaged in the determination of the aromatogram (aromatherapy) have created a unique pharmacokinetics. Essential oils have been shown to have in vitro antiviral activity, including monoterpene alcohols and monoterpene aldehydes. For example, eucalyptol (cineole) is a monoterpene alcohol, which is a common disease in temperate regions and is used for treating respiratory viral infection through the synergistic effect of the cineole and other components in essential oil. Essential oils of various trees in Myrtaceae also have the above synergistic effect. The synergistic effect generated among the components in the essential oil has long been significant in treating various lung diseases. Another pair of compounds, linalool oxide, linalool, is present in essential oils of Hyssopus of f.var decuum bens, for the treatment of viral infections of the lower respiratory tract.
Traditional Chinese medicine essential oil: the systematic application of essential oil is originated from western, and after the system is delivered to China, especially the combination of the essential oil and Chinese traditional medicine in recent years, the Chinese traditional medicine essential oil is also concerned. Combines the four properties of the traditional Chinese medicine, namely cool, cold, warm and hot, and the five tastes of pungent, sweet, sour, bitter and salty, and then looks at where the meridians and the zang-fu organs act, namely the meridians enter. Meanwhile, the healing direction and the efficacy of the essential oil are judged according to the chemical components of the traditional Chinese medicine plants and the plant family. Meanwhile, scientific analysis data are matched, so that the system better corresponds to the system of the oriental.
The "Wenzyi Lun" is a medical book for the first department of China to study acute infectious diseases, and the author is Wu Youthful medical scientist in the late stage of Ming Dynasty. The book of epidemic diseases suggests that the cause of epidemic diseases is either the cause or the cause of the disease. It is considered that the exogenous febrile disease is caused by the natural qi, while the epidemic disease is caused by the natural qi. A new argument is established in China for the first time, wherein the new argument takes the disease resistance of organisms and the warp as causes of diseases. The epidemic treatise states that the infection route of the warp is through air contact and entrance from mouth and nose. A number of new methods for treating infectious diseases are described. For example, it is considered that the original fluid should be used at the beginning of infectious diseases, and the disease is deep, i.e. when pathogenic toxin invades the stomach, it is not necessary to wait for the acute syndrome and attack the stomach. These methods all lay the foundation for the treatment of future infectious diseases.
The microcapsule technology comprises the following steps: the technology for the preparation of microcapsules originated in the 50's of the 20 th century, developed rapidly in the mid 70's, and many microencapsulated products and processes emerged. The microcapsule technology can be widely used in the fields of medicine, food, pesticide, feed, cosmetics, dye, adhesive, carbon paper and the like. The application of microencapsulation technology to pharmaceutical formulations has also been known for a period of four and fifty years, primarily for external use, and then developed for oral administration and for internal muscle tissue. The microcapsule used in the field of medicine is mainly a sustained-release microcapsule, and after a medicine (a core material) and a high-molecular film-forming material (a capsule wall material) are encapsulated into the microcapsule, the medicine is released at a set position at a proper speed and for a sustained time in a form of diffusion, permeation and the like in vivo, so that the aim of exerting the medicine effect to a greater extent is achieved.
Disclosure of Invention
The invention provides a spray, which contains a microcapsule slow-release composition; the microcapsule sustained-release composition comprises the following raw materials in parts by weight: in the composition, octenyl succinate starch ester is taken as a wall material, and the core material comprises 2-10 parts of atractylodes oil, 2-20 parts of patchouli oil, 2-30 parts of angelica dahurica oil, 3-15 parts of eupatorium oil, 3-7 parts of cinnamon oil, 2-8 parts of camphor oil, 5-15 parts of clove oil, 2-25 parts of eucalyptus oil and 2-8 parts of mint oil.
The core material comprises 5 parts of atractylodes oil, 5 parts of patchouli oil, 2 parts of angelica dahurica oil, 6 parts of eupatorium oil, 3 parts of cinnamon oil, 2 parts of camphor oil, 10 parts of clove oil, 8 parts of eucalyptus oil and 2 parts of peppermint oil.
The core material comprises 8 parts of atractylodes oil, 2 parts of patchouli oil, 4 parts of angelica dahurica oil, 8 parts of eupatorium oil, 4 parts of cinnamon oil, 4 parts of camphor oil, 10 parts of clove oil, 10 parts of eucalyptus oil and 3 parts of peppermint oil.
Wherein the core material also comprises nano silver. Preferably 2 to 9 parts of 2000ppm nano silver solution.
Wherein the core material also comprises perilla essential oil. Preferably, the perilla essential oil is used in an amount of 2-20 parts, for example 5-15 parts.
Wherein the content of the starch octenyl succinate is 10-40 parts, such as 30 parts.
Wherein the purity of each essential oil is 70-90%, such as 80%.
Wherein the average particle diameter of the microcapsule is 10-200 μm.
Wherein, the spray also contains a solvent, for example, the solvent is deionized water. Further, the mass fraction of the microcapsule is 10-45%.
The invention also provides a preparation method of the spray, which comprises the following steps:
(1) preparing microcapsule powder: heating starch octenylsuccinate in a water bath environment at 60-90 ℃ for 10-30 min to gelatinize, cooling to room temperature, adding 2-10 parts of atractylodes oil, 2-20 parts of patchouli oil, 2-30 parts of angelica oil, 3-15 parts of eupatorium oil, 3-7 parts of cinnamon oil, 2-8 parts of camphor oil, 5-15 parts of clove oil, 2-25 parts of eucalyptus oil, 2-8 parts of mint oil, 2-9 parts of optional 2000ppm nano silver solution and optional 2-20 parts of perilla essential oil respectively, mixing, dispersing at a high speed of 6000-10000 r/min, and performing spray drying to prepare solid microcapsule powder;
(2) dispersing the microcapsule powder in a solvent to prepare the spray.
Preferably, the core material of the microcapsule powder consists of the following medicinal raw materials in parts by weight: 3-8 parts of atractylodes oil, 4-10 parts of patchouli oil, 3-20 parts of angelica oil, 4-15 parts of eupatorium oil, 3-6 parts of cinnamon oil, 4-8 parts of camphor oil, 3-10 parts of clove oil, 2-10 parts of eucalyptus oil, 3-5 parts of peppermint oil, 2-4 parts of 2000ppm nano-silver solution and 10-30 parts of starch octenyl succinate.
Preferably, the core material of the microcapsule powder consists of the following medicinal raw materials in parts by weight: 10 parts of atractylodes oil, 5 parts of patchouli oil, 4 parts of angelica oil, 8 parts of eupatorium oil, 4 parts of cinnamon oil, 4 parts of camphor oil, 10 parts of clove oil, 10 parts of eucalyptus oil, 3 parts of peppermint oil, 2 parts of 2000ppm nano-silver solution and 30 parts of starch octenyl succinate.
Further, the microcapsule powder takes octenyl succinic acid starch ester as a wall material, 15 parts of atractylodes oil, 3 parts of patchouli oil, 2 parts of angelica oil, 2 parts of eupatorium oil, 5 parts of cinnamon oil, 2 parts of camphor oil, 8 parts of clove oil, 10 parts of eucalyptus oil, 2 parts of peppermint oil and 1 part of 2000ppm nano-silver solution as a core material, the core material is added into the mixture after the mixture is cooled to room temperature and is bathed for 10 min until the octenyl succinic acid starch ester is gelatinized, the mixture is mixed with the core material after being cooled to the room temperature, the mixture is dispersed at a high speed of 9000 r/min for 20min to obtain emulsion medicine microcapsule liquid, and the obtained emulsion is sprayed and dried to obtain solid microcapsule powder. Spray drying conditions: the inlet temperature is 160 ℃, the outlet temperature is 90 ℃, and the material flow is 600 mL/h.
The invention also provides application of the spray or the microcapsule slow-release composition in antibiosis and/or bacteriostasis. Preferably, the bacterium is staphylococcus aureus or the like.
The invention has the beneficial effects that:
the invention provides a spray containing a microcapsule slow-release composition, which is firstly guided by the theory of the traditional Chinese medicine, adopts the modern microcapsule inclusion technology to take microcapsules containing essential oil of a traditional Chinese medicine formula as a spray with an epidemic prevention function, can actively exert the function of killing pathogenic microorganisms in vitro of the essential oil of the traditional Chinese medicine after being sprayed, and has a lasting release effect of antibacterial active ingredients. The microcapsule slow-release composition has no toxic or side effect and adverse reaction, has low spray cost and simple and feasible process, is suitable for industrial production and is suitable for clinical popularization and application.
The specifications of the raw materials of the traditional Chinese medicine composition all accord with the national medical and health standards, and the traditional Chinese medicine composition can be made by oneself or purchased in the market, and the raw material market is sufficiently supplied.
Drawings
FIG. 1 is a graph of wavelength vs. absorbance of clove oil of the present invention.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
Taking octenyl succinic acid starch ester as a wall material, 5 parts of atractylodes oil, 5 parts of patchouli oil, 2 parts of angelica dahurica oil, 6 parts of eupatorium oil, 3 parts of cinnamon oil, 2 parts of camphor oil, 10 parts of clove oil, 8 parts of eucalyptus oil and 2 parts of peppermint oil as core materials, and 2 parts of 2000ppm nano-silver solution.
The preparation process comprises the following steps: water bath is carried out at the temperature of 60-90 ℃ for 10-30 min until starch octenylsuccinate is gelatinized, after cooling to room temperature, 5 parts of rhizoma atractylodis oil, 5 parts of patchouli oil, 2 parts of angelica dahurica oil, 6 parts of eupatorium oil, 3 parts of cinnamon oil, 2 parts of camphor oil, 10 parts of clove oil, 8 parts of eucalyptus oil, 2 parts of peppermint oil and 2 parts of 2000ppm nano silver solution are added for mixing, after high-speed dispersion is carried out for a certain time at the speed of 6000-10000 r/min, the solid microcapsule powder of the medicine is prepared after spray drying. Dispersing the microcapsule powder in deionized water to prepare a spray with microcapsule mass content of 30%.
Example 2
Taking octenyl succinic acid starch ester as a wall material, 5 parts of atractylodes oil, 5 parts of patchouli oil, 2 parts of angelica dahurica oil, 6 parts of eupatorium oil, 3 parts of cinnamon oil, 2 parts of camphor oil, 10 parts of clove oil, 8 parts of eucalyptus oil and 2 parts of peppermint oil as a core material.
The preparation process comprises the following steps: water bath is carried out at 60-90 ℃ for 10-30 min until starch octenylsuccinate is gelatinized, after cooling to room temperature, 5 parts of rhizoma atractylodis oil, 5 parts of patchouli oil, 2 parts of angelica dahurica oil, 6 parts of eupatorium oil, 3 parts of cinnamon oil, 2 parts of camphor oil, 10 parts of clove oil, 8 parts of eucalyptus oil and 2 parts of mint oil are added for mixing, after high-speed dispersion is carried out for a certain time at 6000-10000 r/min, and spray drying is carried out, thus obtaining the solid microcapsule powder of the medicine. Dispersing the microcapsule powder in deionized water to prepare a spray with microcapsule mass content of 24%.
Example 3
The medicine is prepared from the following raw materials in parts by weight: 8 parts of atractylodes oil, 2 parts of patchouli oil, 4 parts of angelica oil, 8 parts of eupatorium oil, 4 parts of cinnamon oil, 4 parts of camphor oil, 10 parts of clove oil, 10 parts of eucalyptus oil, 3 parts of mint oil, 3 parts of perilla essential oil, 2 parts of 2000ppm nano-silver solution and 30 parts of starch octenyl succinate. The influence of the purity of the essential oil on the embedding rate of the microcapsule powder is determined by taking clove oil as a reference.
(1) Determining the maximum absorption wavelength of the clove oil, weighing a certain amount of clove oil, dissolving and diluting the clove oil with absolute ethyl alcohol to prepare a clove oil solution with a certain concentration, taking the absolute ethyl alcohol as a blank control, and performing full-wavelength scanning within the range of 200-900 nm to determine the maximum absorption wavelength.
(2) Drawing a clove oil standard curve, accurately weighing 0.1 g of clove oil into a 10 mL volumetric flask, metering volume by absolute ethyl alcohol, shaking up, pasting a label stock solution, accurately weighing 0.05, 0.1, 0.15, 0.2 and 0.25 mL from the stock solution respectively into five 100 mL volumetric flasks, sequentially pasting labels 1, 2, 3, 4 and 5, metering volume by absolute ethyl alcohol respectively, shaking up, measuring ultraviolet absorbance at the maximum absorption wavelength, repeating for three times, and taking an average value.
(3) Gelatinizing low viscosity starch octenyl succinate aqueous solution (mass fraction of starch octenyl succinate is 30%) in 80 deg.C water bath for 10 min, cooling, and adding Perillae herba essential oil. Mixing the medicinal essential oil raw materials in parts by weight, setting the purity of the essential oil to be 20%, 40%, 60%, 80% and 100% by using a proper amount of absolute ethyl alcohol, dispersing the uniformly mixed solution at a high speed of 9000 r/min for 3 min, performing spray drying on the obtained uniform emulsion to obtain microcapsule powder, and measuring the embedding rate.
(4) The micro-capsule powder embedding rate measurement is carried out by putting 0.2 g of micro powder into 10 mL of absolute ethyl alcohol, carrying out ultrasonic treatment for 15min at 25 ℃ and 800W, then centrifuging for 15min at 4500 r/min, marking as A1, taking 100 mu L of supernatant from A1, putting the supernatant into a volumetric flask, fixing the volume to 10 mL, marking as A2, measuring the absorbance value at 286 nm, carrying out three groups in parallel, calculating the average value, and substituting into a regression equation of a standard curve of perilla essential oil to obtain the surface oil content B1. Adding 20 mL of absolute ethyl alcohol into 2 mL of distilled water 0.2 g of the product, performing ultrasonic treatment at 30 ℃ and 990W for 40 min, adding a proper amount of anhydrous sodium sulfate to remove redundant water, centrifuging at the speed of 5000 r/min for 10 min, marked as A3, taking 100 mu L of supernatant from A3, putting the supernatant into a volumetric flask, fixing the volume to 10 mL, marked as A4, measuring the absorbance value at 286 nm, performing three groups in parallel, calculating the average value, and substituting the average value into a regression equation of a standard curve of the clove oil to obtain the total oil content B2. The embedding rate (%) was calculated as follows:
embedding rate (%) = B2-B1/B2X 100%
As can be seen from FIG. 1, the maximum absorption wavelength of clove oil is 286 nm.
(5) The regression equation of a standard curve drawn by taking the concentration as an X axis and the absorbance value as a Y axis is Y =36.48X-0.0398, and the correlation coefficient is R2=0.9909, the linear relationship between the two is good at 0.004-0.030 mg/mL.
Experimental results the influence of the purity of the essential oil on the embedding rate of the essential oil. The embedding rate of the essential oil shows a trend of increasing and then decreasing along with the increase of the purity of the essential oil. The embedding rate reached a maximum of 40.64% when the purity of the essential oil was 80%. When the purity of the essential oil is too low, the octenyl succinic acid starch ester is remained, and agglomeration and adhesion are easy to occur. When the purity of the essential oil is too high, the octenyl succinic acid starch ester can not be completely wrapped, so that the essential oil is wasted. When the purity of the essential oil exceeds 80%, the embedding rate is rapidly reduced. This is probably because as the purity of the essential oil increases, the wall material around the droplets of the essential oil is too small, the emulsifying effect of the emulsion is reduced, and the thickness and compactness of the capsule wall are reduced, so that the essential oil is easy to seep out of the capsule wall, and the embedding effect is poor. Therefore, the purity of the essential oil is optimal to 80%.
Example 4
And (3) detecting the antibacterial performance: the antibacterial performance of the sustained-release filter layer of the medicament microcapsule of the embodiment 1-2 is determined by an oscillation method according to FZ/T73023-2006 antibacterial knitwear, the used strain is staphylococcus aureus, and the antibacterial performance of the sample is expressed by bacteriostatic rate. The results are shown in Table 1.
TABLE 1 results of antibacterial property test
| Sample (I) | Rate of inhibition of bacteria | Sample (I) | Rate of inhibition of bacteria |
| EXAMPLE 1 preparation of the precoat layer from the microcapsule liquid | 99.6% | EXAMPLE 1 preparation of the precoat layer from microcapsule powder | 98.3% |
| EXAMPLE 2 preparation of the precoat layer from the microcapsule liquid | 98.1% | EXAMPLE 2 preparation of the precoat layer from microcapsule powder | 97.5% |
As can be seen from Table 1, the slow release filter material layer of the drug microcapsule prepared by the invention has excellent antibacterial performance, the bacteriostasis rate to staphylococcus aureus can reach 97.5-99.6%, and compared with the example 1, the example 2 removes the nano-silver component, and the bacteriostasis rate is reduced to some extent, which shows that the nano-silver component added in the invention has synergistic bacteriostasis. Meanwhile, the bacteriostatic effect of the drug microcapsule slow-release filter material layer prepared by the microcapsule liquid is better than that of the drug microcapsule slow-release filter material layer prepared by the solid microcapsule powder.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (10)
1. A spray, comprising a microencapsulated slow release composition; the microcapsule sustained-release composition comprises the following raw materials in parts by weight: in the composition, octenyl succinate starch ester is taken as a wall material, and the core material comprises 2-10 parts of atractylodes oil, 2-20 parts of patchouli oil, 2-30 parts of angelica dahurica oil, 3-15 parts of eupatorium oil, 3-7 parts of cinnamon oil, 2-8 parts of camphor oil, 5-15 parts of clove oil, 2-25 parts of eucalyptus oil and 2-8 parts of mint oil.
2. The spray according to claim 1, wherein the core material comprises 5 parts of atractylodes oil, 5 parts of patchouli oil, 2 parts of angelica dahurica oil, 6 parts of eupatorium oil, 3 parts of cinnamon oil, 2 parts of camphor oil, 10 parts of clove oil, 8 parts of eucalyptus oil and 2 parts of peppermint oil.
3. The spray according to claim 1, wherein the core material comprises 8 parts of atractylodes oil, 2 parts of patchouli oil, 4 parts of angelica dahurica oil, 8 parts of eupatorium oil, 4 parts of cinnamon oil, 4 parts of camphor oil, 10 parts of clove oil, 10 parts of eucalyptus oil and 3 parts of peppermint oil.
4. Spray according to any of claims 1 to 3, characterized in that the core material further comprises nano silver, preferably the core material further comprises perilla essential oil.
5. The spray according to any one of claims 1 to 4, wherein the content of the starch octenylsuccinate is 10 to 40 parts.
6. The spray of any one of claims 1-5, wherein each essential oil has a purity of 70-90%.
7. The spray according to any one of claims 1 to 6, wherein the average particle size of the microcapsule is 10 to 200 μm.
8. The spray according to any one of claims 1 to 7, wherein the spray further comprises solvent deionized water, and the mass fraction of the microcapsule sustained-release composition is 10 to 45%.
9. A process for preparing a spray according to any one of claims 1 to 8, which comprises the steps of:
(1) preparing microcapsule powder: heating starch octenylsuccinate in a water bath environment at 60-90 ℃ for 10-30 min to gelatinize, cooling to room temperature, adding 2-10 parts of atractylodes oil, 2-20 parts of patchouli oil, 2-30 parts of angelica oil, 3-15 parts of eupatorium oil, 3-7 parts of cinnamon oil, 2-8 parts of camphor oil, 5-15 parts of clove oil, 2-25 parts of eucalyptus oil, 2-8 parts of mint oil, optionally perilla essential oil and optionally nano silver, mixing, dispersing at a high speed of 6000-10000 r/min, and spray drying to prepare solid medicine microcapsule powder;
(2) dispersing the microcapsule powder in a solvent to prepare the spray.
10. Use of a spray according to any one of claims 1 to 8 for antibacterial and/or bacteriostatic applications.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010455360.6A CN111727981A (en) | 2020-05-26 | 2020-05-26 | Spray containing microcapsule sustained-release composition and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010455360.6A CN111727981A (en) | 2020-05-26 | 2020-05-26 | Spray containing microcapsule sustained-release composition and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111727981A true CN111727981A (en) | 2020-10-02 |
Family
ID=72647791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010455360.6A Pending CN111727981A (en) | 2020-05-26 | 2020-05-26 | Spray containing microcapsule sustained-release composition and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111727981A (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1631447A (en) * | 2004-12-30 | 2005-06-29 | 浙江理工大学 | Air disinfecting fumigant and its using method |
| CN102274280A (en) * | 2011-08-10 | 2011-12-14 | 华南农业大学 | Patchouli oil microcapsules and preparation method and application thereof |
| CN103054030A (en) * | 2013-01-28 | 2013-04-24 | 天津商业大学 | Method for preparing perilla oil powder through microencapsulation |
| CN103082033A (en) * | 2013-02-06 | 2013-05-08 | 浙江中同科技有限公司 | Instant powdery grease treating starch sodium octenylsuccinate as wall material, and its preparation method |
| CN104069147A (en) * | 2014-06-16 | 2014-10-01 | 南京泽朗医药科技有限公司 | Preparation method of ageratum conyzoides volatile oil microcapsule and antibacterial application thereof |
| CN104226214A (en) * | 2014-09-04 | 2014-12-24 | 南京标科生物科技有限公司 | Preparation method and application of atractylodes lancea volatile oil microcapsules |
| CN109907076A (en) * | 2019-03-29 | 2019-06-21 | 中北大学 | A kind of fire sesame slices essential oil microcapsule powder and its preparation method and application |
| CN110564503A (en) * | 2019-08-05 | 2019-12-13 | 中北大学 | Perilla essential oil microcapsule powder and preparation method and application thereof |
-
2020
- 2020-05-26 CN CN202010455360.6A patent/CN111727981A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1631447A (en) * | 2004-12-30 | 2005-06-29 | 浙江理工大学 | Air disinfecting fumigant and its using method |
| CN102274280A (en) * | 2011-08-10 | 2011-12-14 | 华南农业大学 | Patchouli oil microcapsules and preparation method and application thereof |
| CN103054030A (en) * | 2013-01-28 | 2013-04-24 | 天津商业大学 | Method for preparing perilla oil powder through microencapsulation |
| CN103082033A (en) * | 2013-02-06 | 2013-05-08 | 浙江中同科技有限公司 | Instant powdery grease treating starch sodium octenylsuccinate as wall material, and its preparation method |
| CN104069147A (en) * | 2014-06-16 | 2014-10-01 | 南京泽朗医药科技有限公司 | Preparation method of ageratum conyzoides volatile oil microcapsule and antibacterial application thereof |
| CN104226214A (en) * | 2014-09-04 | 2014-12-24 | 南京标科生物科技有限公司 | Preparation method and application of atractylodes lancea volatile oil microcapsules |
| CN109907076A (en) * | 2019-03-29 | 2019-06-21 | 中北大学 | A kind of fire sesame slices essential oil microcapsule powder and its preparation method and application |
| CN110564503A (en) * | 2019-08-05 | 2019-12-13 | 中北大学 | Perilla essential oil microcapsule powder and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10342840B2 (en) | Nanoparticulate titanium dioxide nanomaterial modified with functional groups and with citric extracts adsorbed on the surface, for the removal of a wide range of microorganisms | |
| Jiang et al. | Electrospun zein/polyoxyethylene core-sheath ultrathin fibers and their antibacterial food packaging applications | |
| CN102499944B (en) | Nanometer silver antibiotic and antiviral compound liquid and its preparation method and products | |
| Seydi et al. | Synthesis of titanium nanoparticles using Allium eriophyllum Boiss aqueous extract by green synthesis method and evaluation of their remedial properties | |
| Hameed et al. | Formulation and evaluation of a clove oil-encapsulated nanofiber formulation for effective wound-healing | |
| Usach et al. | Comparison between citral and pompia essential oil loaded in phospholipid vesicles for the treatment of skin and mucosal infections | |
| Wang et al. | Functionalized textile based therapy for the treatment of atopic dermatitis | |
| Benzaid et al. | Effect of Citrus aurantium L. Essential oil on Streptococcus mutans growth, biofilm formation and virulent genes expression | |
| CN112075459A (en) | Antiviral and antibacterial respiratory tract compound essential oil and preparation method thereof | |
| Fadaka et al. | Broad spectrum anti-bacterial activity and non-selective toxicity of gum Arabic silver nanoparticles | |
| CN101889593B (en) | Functional incense and preparation method and application thereof | |
| Trivedi et al. | Recent advancements in plant-derived nanomaterials research for biomedical applications | |
| Pauli et al. | Specific selection of essential oil compounds for treatment of children’s infection diseases | |
| Haufe et al. | Bioactive textiles by sol–gel immobilised natural active agents | |
| Volmajer Valh et al. | Microencapsulation of cannabidiol in liposomes as coating for cellulose for potential advanced sanitary material | |
| Pagano et al. | Emulgel loaded with flaxseed extracts as new therapeutic approach in wound treatment | |
| Kahdim et al. | Fabrication of a polycaprolactone/Chitosan nanofibrous scaffold loaded with nigella sativa extract for biomedical applications | |
| CN106359472A (en) | Bactericidal compound essential oil and preparation method of same | |
| Uhlířová et al. | Antimicrobial activity of gelatin nanofibers enriched by essential oils against Cutibacterium acnes and Staphylococcus epidermidis | |
| CN111727981A (en) | Spray containing microcapsule sustained-release composition and preparation method and application thereof | |
| CN111228335A (en) | Epidemic prevention functional mask drug microcapsule slow-release filter material composition | |
| Chamsai et al. | Topical film-forming chlorhexidine gluconate sprays for antiseptic application | |
| CN114432206A (en) | Nano sustained-release microcapsule and preparation method and application thereof | |
| Muresan et al. | Dental Hydrogels with Essential Oils with Potential Activity in Periodontitis | |
| Yang et al. | Biocompatibility and antimicrobial activity of Reynoutria elliptica extract for dental application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201002 |
|
| RJ01 | Rejection of invention patent application after publication |